Survival after curative hepatectomy for hepatocellular carcinoma in patients with and without MAFLD: a western cohort study
Frontiers in Oncology · 16.07.2026 · 16
DOI: 10.3389/fonc.2026.1793271 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Frontiers in Oncology, online erschienen am 16.07.2026. Verfasst von Michele Molinari und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, United States. Die Arbeit nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Evidence suggesting that hepatocellular carcinoma (HCC) arising in patients with metabolic-associated fatty liver disease (MAFLD) is associated with better outcomes than HCC related to other liver diseases has been derived largely from non-Western cohorts and has incompletely accounted for the severity of underlying liver disease. Whether MAFLD independently influences survival after hepatic resection, particularly in Western populations, remains uncertain.
Methods
In this retrospective single-center cohort study, adults who underwent curative-intent hepatic resection for HCC at a Western academic center were evaluated. Patients managed without surgery were excluded. MAFLD was defined according to international consensus criteria. In the primary analysis, patients were classified as MAFLD-positive if they fulfilled MAFLD criteria and had no competing chronic liver disease etiology. Overall survival (OS) and disease-free survival (DFS) were assessed with Cox proportional-hazards models adjusted for cirrhosis, albumin-bilirubin grade, tumor burden, performance status, and alpha-fetoprotein level among other confounders.
Results
Among 156 patients, 89 (57.1%) were classified as MAFLD-positive. As compared with MAFLD-negative patients, MAFLD-positive patients were older, more frequently obese and diabetic, and less likely to have cirrhosis (all P ≤ 0.043). Open or hybrid resection was more common in the MAFLD-positive group, whereas minimally invasive resection was more common in the MAFLD-negative group (67.4% vs. 44.8% and 32.6% vs. 55.2%, respectively; P = 0.006). In unadjusted analyses, MAFLD-positive status was associated with longer DFS and a trend towards longer OS; however, these associations were attenuated after multivariable adjustment. MAFLD was not independently associated with OS (adjusted hazard ratio, 0.91; 95% confidence interval [CI], 0.45 to 1.84; P = 0.785) or DFS (adjusted hazard ratio, 0.58; 95% CI, 0.28 to 1.19; P = 0.139). Cirrhosis, impaired performance status, elevated alpha-fetoprotein, and greater tumor burden were the principal predictors of postoperative outcomes.
Conclusions
In this Western resection cohort, MAFLD was not independently associated with OS or DFS after curative hepatectomy once liver disease severity and tumor burden were taken into account. Prognosis was driven primarily by established hepatic and oncologic factors rather than metabolic etiology alone.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, United States.
- Department of Surgery, Kaohsiung Medical University, Kaohsiung, Taiwan.
- University of Pittsburgh, Pittsburgh, PA, United States.
- Department of Surgery, Houston Methodist Hospital, Houston, TX, United States.
Zitieren
APA
Molinari, M., Sethi, V., Kaltenmeier, C., Abdullah, A., Demirors, B., Yu-Sheng Lin, M., Mial-Anthony, J., Arefan, D., Wu, S., Buros, C., Liu, H., Elias, C., Minervini, M., Tohme, S., Zhang, X., Geller, D., & Furlan, A. (2026). Survival after curative hepatectomy for hepatocellular carcinoma in patients with and without MAFLD: a western cohort study. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1793271
Vancouver
Molinari M, Sethi V, Kaltenmeier C, Abdullah A, Demirors B, Yu-Sheng Lin M, et al. Survival after curative hepatectomy for hepatocellular carcinoma in patients with and without MAFLD: a western cohort study. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1793271
BibTeX
@article{Molinari2026,
author = {Molinari, Michele and Sethi, Vrishketan and Kaltenmeier, Christof and Abdullah, Abiha and Demirors, Berkay and Yu-Sheng Lin, Matthew and Mial-Anthony, Jason and Arefan, Dooman and Wu, Shandong and Buros, Christopher and Liu, Hao and Elias, Charbel and Minervini, Marta and Tohme, Samer and Zhang, Xingyu and Geller, David and Furlan, Alessandro},
title = {Survival after curative hepatectomy for hepatocellular carcinoma in patients with and without MAFLD: a western cohort study},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.1793271}
}
EUVIMED